- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06096116
심폐 우회술이 필요한 심장 수술을 받아야 하는 헤파린 저항성 환자에서 인간 혈장 유래 항트롬빈(Atenativ)의 유효성 및 안전성에 대한 3상 연구
심폐 우회술이 필요한 심장 수술을 받아야 하는 헤파린 저항성 환자에 대한 인간 혈장 유래 항트롬빈(Atenativ)의 효능 및 안전성에 대한 제3상, 이중 맹검, 위약 대조, 다기관 연구
The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Cristina Solomon, MD
- 전화번호: +41 79 585 90 42
- 이메일: Cristina.Solomon@octapharma.com
연구 장소
-
-
-
Bucharest, 루마니아
- 모병
- Institute for Cardiovascular Diseases C.C. Iliescu
-
-
-
-
-
Kaunas, 리투아니아
- 종료됨
- Hospital of Lithuanian university of Health sciences Kauno Klinikos
-
Vilnius, 리투아니아
- 모병
- Vilnius University hospital Santaros Klinikos
-
-
-
-
California
-
Stanford, California, 미국, 94305-5101
- 모병
- Stanford University School of Medicine
-
-
Florida
-
Miami, Florida, 미국, 33136
- 모병
- University of Miami
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- 모병
- Massachusetts General Hospital
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710-1000
- 모병
- Duke University Medical Center
-
Winston-Salem, North Carolina, 미국, 27157
- 모병
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cleveland, Ohio, 미국, 44195
- 모병
- Cleveland Clinic
-
Columbus, Ohio, 미국, 43214
- 모병
- The Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73104
- 모병
- OU Health University of Oklahoma Medical Center
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern Medical Center
-
-
-
-
-
Kamenitz, 세르비아
- 모병
- Institute of Cardiovascular Diseases Vojvodina
-
-
-
-
-
Ljubljana, 슬로베니아
- 모병
- University Medical Centre Ljubljana
-
-
-
-
-
Cambridge, 영국
- 모병
- Royal Papworth Hospital
-
Coventry, 영국
- 모병
- University Hospital Coventry and Warwickshire
-
Middlesbrough, 영국
- 모병
- The James Cook University Hospital
-
-
-
-
-
Innsbruck, 오스트리아
- 모병
- University Hospital Innsbruck
-
Vienna, 오스트리아
- 모병
- Vienna General Hospital AKH, Medical University of Vienna
-
-
-
-
-
Brno, 체코
- 모병
- Center of Cardiovascular and Transplant Surgery
-
Prague, 체코
- 종료됨
- Institute for Clinical and Experimental Medicine
-
-
-
-
British Columbia
-
New Westminster, British Columbia, 캐나다, V3L0A4
- 모병
- Royal Columbian Hospital
-
-
Ontario
-
Kingston, Ontario, 캐나다, K7L2V7
- 모병
- Kingston Health Sciences Centre
-
Toronto, Ontario, 캐나다, M5G2C4
- 아직 모집하지 않음
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, 캐나다, H1T1C8
- 모병
- Montreal Heart Institute
-
-
-
-
-
Reims, 프랑스
- 종료됨
- CHU de Reims, Hôpital Robert Debré
-
Rennes, 프랑스
- 빼는
- CHU de Rennes
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Planned cardiac surgery with CPB
- Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
- Patients between 18 and 85 years of age, inclusive
- Freely given written or electronic informed consent
- In female patients of childbearing potential, a pre-existing negative pregnancy test within 14 days prior to surgery
Exclusion Criteria:
-
Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:
- vitamin K antagonists (within 3 days)
- direct oral anticoagulants (within 2 days)
- thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
- glycoprotein IIb/IIIa antagonist (within 24 hours)
-
Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)
-
Renal insufficiency, defined as serum creatinine level >2.0 mg/dL
-
Thrombocytosis, defined as platelet count >400,000 per μL
-
Known hypersensitivity or allergic reaction to antithrombin or any of the excipients in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid
-
History of anaphylactic reaction(s) to blood or blood components
-
Refusal to receive transfusion of blood or blood-derived products
-
Current participation in another interventional clinical trial or previous participation in the current trial
-
Treatment with any IMP within 30 days prior to screening visit
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low-dose Atenativ
Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
실험적: High-dose Atenativ
Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ. |
A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma |
|
위약 비교기: Placebo
Patients will receive a saline bolus dose |
Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Restoring heparin responsiveness
기간: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Amounts of further therapy for restoring heparin responsiveness
기간: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Change in activated clotting time (ACT) values
기간: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo |
Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion
|
|
Change in antithrombin plasma levels
기간: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo |
Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion
|
|
Change in heparin usage
기간: From end of IMP infusion to the end of surgery
|
The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo |
From end of IMP infusion to the end of surgery
|
|
FP unit use
기간: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first
|
|
Amounts of further antithrombin concentrate for maintaining heparin responsiveness
기간: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first) |
From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first
|
|
Transfusion of allogenic blood products
기간: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between transfusion of other allogeneic blood products (e.g., red blood cells [RBCs], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of coagulation factor concentrates
기간: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Administration of other haemostatic-relevant therapies
기간: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively |
From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Postoperative chest tube drainage
기간: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first |
From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first
|
|
Need for reoperation due to bleeding
기간: 24 hours after the start of IMP infusion
|
Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical) |
24 hours after the start of IMP infusion
|
|
Cell saver volume
기간: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
The comparison between cell saver volume until the end of surgery |
During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)
|
|
Adverse events
기간: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
Incidence of adverse events, including all related and non-related, non-serious adverse events |
From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first
|
|
Serious adverse events
기간: From the start of IMP infusion until 28 days after IMP administration
|
Incidence of serious adverse events |
From the start of IMP infusion until 28 days after IMP administration
|
|
Survival status
기간: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
Number of patients surviving in all three cohorts |
At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration
|
|
Red Blood Cell count
기간: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
White Blood Cell count
기간: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haemoglobin levels
기간: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion
|
|
Haematocrit
기간: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
|
Platelet count
기간: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
Standard haematological parameter |
Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ATN-108
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .